Published in Mol Vis on November 04, 2014
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
Transforming growth factor-beta induces development of the T(H)17 lineage. Nature (2006) 25.91
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature (1990) 11.92
Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev (1999) 9.94
Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A (1997) 7.52
A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature (2005) 6.83
TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med (2007) 5.41
The PPARalpha-leukotriene B4 pathway to inflammation control. Nature (1996) 5.14
Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell (2005) 4.30
PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med (2001) 4.17
Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem (1999) 3.57
Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem (1997) 3.55
Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem (2000) 1.95
The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J Mol Endocrinol (1993) 1.69
Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol (2004) 1.62
Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis. Int Rev Immunol (2002) 1.38
Bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization in multifocal choroiditis. Retina (2009) 1.33
Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia. J Neurosci Res (2005) 1.32
Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown. J Neurosci Res (1997) 1.29
Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford) (2009) 1.25
Nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent. J Biol Chem (2001) 1.15
Marrow-derived activated macrophages are required during the effector phase of experimental autoimmune uveoretinitis in rats. Curr Eye Res (1998) 1.14
Constitutive activation of NF-kappa B in an animal model of aging. Int Immunol (1997) 1.14
Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J Neuroimmunol (2006) 1.13
WY14,643, a PPAR alpha ligand, has profound effects on immune responses in vivo. J Immunol (2002) 1.09
Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol (2001) 1.08
Induction of nestin, Ki-67, and cyclin D1 expression in Müller cells after laser injury in adult rat retina. Graefes Arch Clin Exp Ophthalmol (2005) 1.06
Intravitreal bevacizumab (avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina (2007) 1.06
Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis. Graefes Arch Clin Exp Ophthalmol (2008) 1.04
Repression of IFN-gamma expression by peroxisome proliferator-activated receptor gamma. J Immunol (2004) 1.04
Effect of macrophage depletion by liposomes containing dichloromethylene-diphosphonate on endotoxin-induced uveitis. J Neuroimmunol (1998) 0.97
Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt-Koyanagi-Harada syndrome. Jpn J Ophthalmol (2009) 0.95
Increased vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGFbeta) in experimental autoimmune uveoretinitis: upregulation of VEGF without neovascularization. J Neuroimmunol (1998) 0.91
S-antigen: identification of the MAbA9-C6 monoclonal antibody binding site and the uveitopathogenic sites. Curr Eye Res (1986) 0.89
Ocular transfer of retinal glial cells transduced ex vivo with adenovirus expressing viral IL-10 or CTLA4-Ig inhibits experimental autoimmune uveoretinitis. Gene Ther (2003) 0.88
Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate. Exp Eye Res (2005) 0.86
Suppression of experimental autoimmune uveoretinitis by anti-alphabeta TCR monoclonal antibody. Jpn J Ophthalmol (2002) 0.77
The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: a pilot study. Rheumatol Int (2012) 0.77
Ultrasmall-incision bimanual phacoemulsification and AcrySof SA30AL implantation through a 2.2 mm incision. J Cataract Refract Surg (2003) 1.97
Use of the phaco tip technique for lens cleavage and removal during cataract surgery. Clin Ophthalmol (2016) 1.40
6.5 mm optic AcrySof implantation through a 3.0 mm incision. J Cataract Refract Surg (2003) 1.39
Spontaneous resolution of foveal detachment in dome-shaped macula observed by spectral domain optical coherence tomography. Clin Ophthalmol (2013) 0.94
Bilateral tonic pupils associated with neurosyphilis. Jpn J Ophthalmol (2003) 0.83
Three-year visual outcomes of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy. Acta Ophthalmol (2016) 0.79
Use of DNA microarray analysis in diagnosis of bacterial and fungal endophthalmitis. Clin Ophthalmol (2012) 0.79
Three-year visual outcome of photodynamic therapy plus intravitreal bevacizumab with or without subtenon triamcinolone acetonide injections for polypoidal choroidal vasculopathy. Br J Ophthalmol (2014) 0.76
Comparison of standard automated perimetry with matrix frequency-doubling technology in patients with resolved optic neuritis. Ophthalmology (2007) 0.75
Prefilled syringes and usability of ophthalmic viscosurgical devices. Clin Ophthalmol (2014) 0.75
Presumed toxoplasmic central retinal artery occlusion and multifocal retinitis with perivascular sheathing. Clin Ophthalmol (2014) 0.75
Differences in Neuroticism Between Patients with Glaucoma Who Have Discontinued Visits to Ophthalmologists and Those Who Make Regular Visits: Implications for Adherence to Topical Glaucoma Medications. Ophthalmol Ther (2016) 0.75
Perioperative changes of the intraocular pressure during the treatment of epiretinal membrane by using 25- or 27-gauge sutureless vitrectomy without gas tamponade. Clin Ophthalmol (2017) 0.75
Factors influencing self-sealing of sclerotomy performed under gas tamponade in 23-gauge transconjunctival sutureless vitrectomy. Clin Ophthalmol (2014) 0.75
Twenty-Four-Hour Variation of Intraocular Pressure in Primary Open-Angle Glaucoma Treated with Triple Eye Drops. J Ophthalmol (2017) 0.75
Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol (2021) 0.75